# US 7,611,884 B2 · Toxoplasma gondii nucleic acid molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,884 B2
- Document ID: US7611884B2
- Status: Granted
- Kind: B2
- Application number: 12/138,512
- Filed: 2008-06-13
- Published: 2009-03-12
- Granted: 2009-11-03
- Earliest claimed: 1997-12-19
- Assignees: Heska Corporation
- Inventors: Michael James Milhausen
- Web page: https://patentgrep.com/patent/US7611884B2

## CPC

- C07K 14/45: Toxoplasma
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- C12N 2799/021: for the expression of a heterologous nucleic acid
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such compositions to inhibit oocyst shedding by cats due to infection with T. gondii. The present invention also includes the use of certain T. gondii-based antisera to identify such nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins identified by such methods. The present invention also relates to novel methods for the detection of cysts and oocysts.

## Claims

### Claim 1

An isolated nucleic acid molecule selected from the group consisting of:
(a) a nucleic acid molecule that hybridizes to an at least 18 contiguous nucleotide region of SEQ ID NO:72 under conditions comprising (1) hybridizing in a solution comprising 2X SSC in the absence of nucleic acid double helix destabilizing compounds, at a temperature of about 37° C.; and (2) washing in a solution comprising 1×SSC in the absence of double helix destabilizing compounds at a temperature of about 74° C.; and
(b) a nucleic acid molecule fully complementary in sequence to the nucleic acid molecule of (a).

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is selected from the group consisting of:
(a) an isolated nucleic acid molecule that comprises a nucleic acid sequence at least 95% identical to the nucleic acid sequence represented by SEQ ID NO:72; and
(b) an isolated nucleic acid molecule fully complementary in sequence to the nucleic acid molecule of (a).

### Claim 3 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is selected from the group consisting of:
(a) an isolated nucleic acid molecule that comprises a nucleic acid sequence represented by SEQ ID NO:72; and
(b) an isolated nucleic acid molecule fully complementary in sequence to the nucleic acid molecule of (a).

### Claim 4 (depends on 1)

A recombinant virus comprising an isolated nucleic acid molecule as set forth in claim 1.

### Claim 5 (depends on 1)

A recombinant cell comprising an isolated nucleic acid molecule as set forth in claim 1.

### Claim 6 (depends on 1)

A composition comprising (a) an isolated nucleic acid molecule as set forth in claim 1, and (b) a component selected from the group consisting of an excipient, an adjuvant and a carrier.

### Claim 7

An isolated nucleic acid molecule selected from the group consisting of:
(a) an isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a protein comprising an amino acid sequence at least 95% identical to SEQ ID NO:73; and
(b) an isolated nucleic acid molecule fully complementary in sequence to the nucleic acid molecule of (a).

### Claim 8 (depends on 7)

The isolated nucleic acid molecule of claim 7, wherein said isolated nucleic acid molecule is selected from the group consisting of:
(a) an isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a protein comprising SEQ ID NO:73; and
(b) an isolated nucleic acid molecule fully complementary in sequence to the nucleic acid molecule of(a).

### Claim 9 (depends on 7)

The isolated nucleic acid molecule of claim 7, wherein said isolated nucleic acid molecule is selected from the group consisting of:
(a) an isolated nucleic acid molecule consisting of a nucleic acid sequence that encodes a protein comprising an amino acid sequence at least 95% identical to SEQ ID NO:73; and
(b) an isolated nucleic acid molecule fully complementary in sequence to the nucleic acid molecule of (a).

### Claim 10 (depends on 7)

A recombinant virus comprising an isolated nucleic acid molecule as set forth in claim 7.

### Claim 11 (depends on 7)

A recombinant cell comprising an isolated nucleic acid molecule as set forth in claim 7.

### Claim 12 (depends on 7)

A composition comprising (a) an isolated nucleic acid molecule as set forth in claim 7, and (b) a component selected from the group consisting of an excipient, an adjuvant and a carrier.